MDM2 and central nervous system cancer: In this context, it would be of practical interest and importance to examine whether AMG232 and BI-907828, novel MDM2 inhibitors demonstrated to be highly potent in glioma stem cells, have such a marked differential effect in stem and non-stem glioma cells as RG7112 does.